What is PureForm Global?
Headquartered in Los Angeles, PureForm Global operates at the intersection of advanced chemistry and pharmaceutical manufacturing. The company specializes in the research, development, and commercialization of synthetic cannabinoids that are chemically identical to plant-derived compounds. By utilizing a proprietary, scalable manufacturing process, PureForm eliminates the variability associated with traditional agricultural sourcing. Their production facilities in the United States and the United Kingdom adhere to strict cGMP and FDA standards, ensuring that their output is free from THC, pesticides, and other impurities. This commitment to purity and consistency positions PureForm as a critical supply chain partner for industries requiring high-grade, stable cannabinoid ingredients.
How much funding has PureForm Global raised?
PureForm Global has raised a total of $125K across 1 funding round:
Debt
$125K
Debt (2021): $125K with participation from PPP
Key Investors in PureForm Global
PPP
Public-Private Partnership
What's next for PureForm Global?
With this recent capital injection, PureForm Global is poised to scale its commercial operations and deepen its market penetration. The company is expected to leverage these funds to optimize its proprietary manufacturing processes further and expand its footprint in the global pharmaceutical and wellness markets. As the regulatory landscape for cannabinoids continues to evolve, PureForm's ability to provide a consistent, synthetic alternative offers a distinct competitive advantage. Future strategic initiatives will likely focus on increasing production capacity to meet rising demand while maintaining the high-quality standards that define their current market position.
See full PureForm Global company page
